Orthofix International N.V. (NASDAQ:OFIX) Director Luke T. Faulstick sold 4,800 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $51.22, for a total transaction of $245,856.00. Following the transaction, the director now directly owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Orthofix International N.V. (NASDAQ:OFIX) opened at $51.44 on Friday. The company has a market cap of $943.09, a PE ratio of 33.81, a PEG ratio of 2.57 and a beta of 0.15. Orthofix International N.V. has a 52-week low of $32.51 and a 52-week high of $54.33.

Orthofix International N.V. (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Orthofix International N.V. had a net margin of 0.33% and a return on equity of 10.26%. The firm had revenue of $105.30 million during the quarter, compared to analyst estimates of $100.67 million. During the same quarter in the prior year, the business posted $0.36 earnings per share. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. equities research analysts predict that Orthofix International N.V. will post 1.61 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/orthofix-international-n-v-ofix-director-sells-245856-00-in-stock/1695705.html.

A number of large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in Orthofix International N.V. by 109.2% in the third quarter. Wells Fargo & Company MN now owns 27,749 shares of the medical device company’s stock worth $1,311,000 after purchasing an additional 14,482 shares in the last quarter. Paradice Investment Management LLC raised its position in Orthofix International N.V. by 10.0% in the third quarter. Paradice Investment Management LLC now owns 157,200 shares of the medical device company’s stock worth $7,428,000 after purchasing an additional 14,300 shares in the last quarter. Cadence Capital Management LLC acquired a new position in Orthofix International N.V. in the third quarter worth about $1,501,000. Citadel Advisors LLC raised its position in Orthofix International N.V. by 83.2% in the third quarter. Citadel Advisors LLC now owns 11,313 shares of the medical device company’s stock worth $535,000 after purchasing an additional 5,138 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Orthofix International N.V. by 4.5% in the third quarter. JPMorgan Chase & Co. now owns 245,495 shares of the medical device company’s stock worth $11,654,000 after purchasing an additional 10,580 shares in the last quarter. 93.81% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on OFIX. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Orthofix International N.V. in a research report on Thursday, August 10th. Zacks Investment Research lowered shares of Orthofix International N.V. from a “buy” rating to a “hold” rating in a research report on Wednesday. BidaskClub lowered shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. TheStreet lowered shares of Orthofix International N.V. from a “b” rating to a “c+” rating in a research report on Tuesday, October 31st. Finally, BTIG Research set a $56.00 price objective on shares of Orthofix International N.V. and gave the company a “buy” rating in a research report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Orthofix International N.V. has an average rating of “Buy” and a consensus price target of $54.42.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.